|
|
||||||||
Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin
Submitted 18 August 2004 ; accepted in final form 18 October 2004
Angiogenesis within an ischemic region of the brain may increase tissue viability and act to limit the extent of an infarct. The ANG II pathway can both stimulate and inhibit angiogenesis depending on the tissue and the activated receptors. Previous work showed that 2-wk losartan administration (ANG II type 1 receptor blockade) initiates a significant cerebral angiogenic response. We hypothesized that administration of losartan in the drinking water of rats for 2 wk before initiation of focal ischemia would decrease the extent of the resulting infarct. Adult male Sprague-Dawley rats were given losartan (50 mg/day) in drinking water for 2 wk before initiation of cerebral focal ischemia produced by cauterization of cortical surface vessels. Controls received normal drinking water. In control animals, three main vessels feeding the whisker barrel cortex were cauterized, resulting in cessation of blood flow. The same protocol was followed for losartan-treated animals but did not result in cessation of blood flow in the whisker barrel cortex. Another group of losartan-treated animals received between 8 and 14 cauterizations of surface vessels feeding the whisker barrel cortex, and cessation of blood flow was verified. Rats were killed 72 h after surgery. Morphological examination revealed angiogenesis, maintained vascular delivery, and significantly decreased infarct size in losartan-treated animals compared with controls. These results demonstrate that pretreatment with losartan reduces infarct size after cerebral focal ischemia and support the hypothesis that cerebral angiogenesis may be one of the mechanisms responsible.
cerebrovascular regulation; rat model; losartan; stroke
This article has been cited by other articles:
![]() |
S. Chen, G. Li, W. Zhang, J. Wang, C. D. Sigmund, J. E. Olson, and Y. Chen Ischemia-induced brain damage is enhanced in human renin and angiotensinogen double-transgenic mice Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2009; 297(5): R1526 - R1531. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Kozak, A. Kozak, M. H. Johnson, H. F. Elewa, and S. C. Fagan Vascular Protection with Candesartan after Experimental Acute Stroke in Hypertensive Rats: A Dose-Response Study J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 773 - 782. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-S. Sun, T. A. Doucette, Y. Liu, Y. Fang, L. Teves, M. Aarts, C. L. Ryan, P. B. Bernard, A. Lau, J. P. Forder, et al. Effectiveness of PSD95 Inhibitors in Permanent and Transient Focal Ischemia in the Rat Stroke, September 1, 2008; 39(9): 2544 - 2553. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Munzenmaier and A. S. Greene Chronic angiotensin II AT1 receptor blockade increases cerebral cortical microvessel density Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H512 - H516. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |